Search | Médecins Sans Frontières Access Campaign

78 results found

Vials of liposomal amphotericin B (L-AmB)

Press release |

03 May 2023

MSF calls on Gilead to finally fulfil access promise and make lifesaving drug for people with HIV available where needed

Gilead hikes price while liposomal amphotericin B (L-AmB) for treatment of HIV-related cryptococcal meningitis remains unavailable and unaffordable in countries where it’s most needed

Tags HIV/AIDS cryptococcal meningitis liposomal amphotericin B Gilead

Video |

03 May 2023

Access challenges for HIV opportunistic infection drug L-AmB

MSF Access Campaign answers three questions on the challenges accessing liposomal amphotericin B (L-AmB), a key drug for treating the deadly HIV opportunistic infection cryptococcal meningitis.

Tags HIV/AIDS cryptococcal meningitis

Research article |

29 August 2022

Clinical Infectious Diseases: Access to medicines for treating people with cryptococcal meningitis

MSF, Unitaid and WHO authors discuss the need to improve access to liposomal amphotericin B (L-AmB) for the treatment of HIV-associated cryptococcal meningitis.

Tags HIV/AIDS cryptococcal meningitis liposomal amphotericin B UNITAIDWorld Health Organization

Cryptococcal disease facts and barriers to access

Infographic

Cryptococcal meningitis

Cryptococcal meningitis is an opportunistic fungal infection, which is the number two killer of people living with HIV/AIDS after tuberculosis. With timely and effective diagnosis and treatment, people living with HIV/AIDS can survive ...

Tags HIV/AIDS cryptococcal meningitis liposomal amphotericin B

Press release |

20 April 2022

MSF responds to new simplified WHO treatment guidelines for cryptococcal meningitis, the number two killer of people living with HIV/AIDS

MSF urges all countries to adopt the guidelines and outlines the actions needed to make the WHO-recommended treatment accessible to people who need it

Tags HIV/AIDS cryptococcal meningitis liposomal amphotericin B World Health Organization

Issue brief |

16 December 2021

Liposomal amphotericin B: Solving the access puzzle

Liposomal amphotericin B is a lifesaving treatment for several diseases. Collaborative work among stakeholders is essential to overcome persistent access barriers.

Tags COVID-19HIV/AIDSTropical & neglected diseases mucormycosiscryptococcal meningitisvisceral leishmaniasis (kala azar) liposomal amphotericin B UNAIDS

Finda collects her six months of ART and related drugs at MSF-supported pharmacy as part of her months consultation at the MSF-supported HIV outpatient department at Matam health centre, Conakry, Guinea

Opinion article |

01 December 2021

This World AIDS Day: How to defeat cryptococcal meningitis, an outsider

Thousands of deaths from a fungal infection of the brain called cryptococcal meningitis (CM) could potentially be averted every year in South Africa if an antifungal medicine called flucytosine is widely available.

Tags HIV/AIDS cryptococcal meningitisHIV/AIDS

Statement |

01 December 2021

MSF statement at WHA Special Session, 29 Nov - 1 Dec 2021

MSF statement at World Health Assembly Special Session on COVID-19, calling for people-centred, equitable, inclusive, open and transparent process.

Tags HIV/AIDS cryptococcal meningitisHIV/AIDS World Health Assembly

Press release |

21 July 2021

Breakthrough in treatment of HIV-related cryptococcal meningitis gives Gilead another opportunity to fulfil its promise to scale up access to lifesaving drug

Following a breakthrough in treatment of HIV-related cryptococcal meningitis, MSF urges Gilead to immediately scale up access to lifesaving drug L-AmB

Tags HIV/AIDS cryptococcal meningitis liposomal amphotericin B World Health OrganizationGilead

David was admitted at the HBCTRH after he falling sick. He had cryptococcal meningitis and Karposi Sarcoma – a kind of cancer common among HIV-positive patients who are failing treatment. The KS had affected his left leg as well and he has to walk using supports.

Press release |

13 May 2021

Ending deaths from cryptococcal meningitis in a decade is possible – but more action needed before UN meeting on HIV/AIDS

A coalition of African, European and American institutions, including MSF, launched today a strategic framework calling the end of deaths from cryptococcal meningitis by 2030.

Tags HIV/AIDS cryptococcal meningitis

Report |

13 May 2021

Ending cryptococcal meningitis deaths by 2030: Strategic framework

This Strategic Framework sets out the case for a re-invigorated global drive to end cryptococcal meningitis deaths by 2030, as part of a broader drive to end all HIV-related deaths, and outlines what essential programmatic elements are ...

Tags HIV/AIDS cryptococcal meningitis UNAIDSWorld Health Organization

Press release |

07 October 2019

Urgent boost and ‘reality check’ needed for HIV and TB funding, says new MSF report

After a decade of strong commitments to fight the twin epidemics of HIV and tuberculosis (TB), a decline in international funding and the rapid shifting of the financial burden to affected countries is in danger of reversing lifesaving ...

Tags HIV/AIDSMalariaTuberculosis HIV/AIDSmalariatuberculosis Global Fund

Report |

07 October 2019

Burden sharing or burden shifting?

Tags HIV/AIDSTuberculosis HIV/AIDStuberculosis Global Fund

Gloria Chipasula (Center), 11 years old, and her mother Teleza James (Right) sit in Milepa Health Centre's consulting room as Ministry of Health’s nurse Violet Banda (Left performs a standard medical examination for HIV patients.

Photograph Luca Sola

Blog |

06 September 2019

We’re all still waiting, Gilead ...

One year after the pharmaceutical corporation Gilead Sciences promised lower prices for a key drug for people with advanced HIV, why are people still waiting for this lifesaving treatment? Jess Burry, a pharmacist in the Access Campaign, asks if Gilead’s promise is just one big PR stunt.

Technical brief |

19 July 2019

Beware the Global Fund Procurement Cliff

Tags HIV/AIDSTuberculosis HIV/AIDSmalariatuberculosis The Global Drug Facility

Press release |

27 June 2019

Gilead Sciences fails on promise to expand access to lifesaving drug for people living with HIV

Inaction by US pharmaceutical corporation Gilead to follow through on its so-called ‘access initiative’ leaves people unable to access a vital drug to treat a deadly infection.

Tags HIV/AIDS cryptococcal meningitisHIV/AIDS Gilead

Feature story

Then & Now in Access to Medicines: Changes & Challenges

Tags Hepatitis CHIV/AIDSResearch and developmentTuberculosisVaccines Ebolahepatitis CHIV/AIDSsleeping sicknesstuberculosis Access Campaign: 20 Years

Press release |

13 November 2018

Hundreds of thousands of people’s treatment at risk as countries ‘transition’ from Global Fund support

MSF calls on Global Fund Board to make urgent changes to prevent drug stock-outs and quality issues.

Tags HIV/AIDSTuberculosis HIV/AIDStuberculosis stock out

Vials of Amphotericin B which is used to treat Cryptococcal Meningitis, an opportunistic infection affecting very low immunity from HIV patients.

Letter |

25 July 2018

MSF Access calls on Gilead to urgently make its life-saving cryptococcal meningitis treatment more accessible and affordable

Tags HIV/AIDS cryptococcal meningitisHIV/AIDS antiretroviral medicines diagnostic testsstock out World Health OrganizationGilead

An MSF nurse performs a Cryptococcal Antigen (CrAg) screening test to test for Cryptococcal Meningitis in an AIDS patient.

Letter |

24 July 2018

MSF calls on Mylan to urgently make its life-saving cryptococcal meningitis treatment more accessible and affordable

Tags HIV/AIDS cryptococcal meningitis antiretroviral medicines opportunistic infectionsWHO pre-qualification World Health Organization

Date

Primary topics

Types of content

Products

Diseases

General Terms

Geography

Campaigns

Institutions & Events

Report series

Miscellaneous

MSF calls on Gilead to finally fulfil access promise and make lifesaving drug for people with HIV available where needed

Access challenges for HIV opportunistic infection drug L-AmB

Clinical Infectious Diseases: Access to medicines for treating people with cryptococcal meningitis

Cryptococcal meningitis

MSF responds to new simplified WHO treatment guidelines for cryptococcal meningitis, the number two killer of people living with HIV/AIDS

Liposomal amphotericin B: Solving the access puzzle

This World AIDS Day: How to defeat cryptococcal meningitis, an outsider

MSF statement at WHA Special Session, 29 Nov - 1 Dec 2021

Breakthrough in treatment of HIV-related cryptococcal meningitis gives Gilead another opportunity to fulfil its promise to scale up access to lifesaving drug

Ending deaths from cryptococcal meningitis in a decade is possible – but more action needed before UN meeting on HIV/AIDS

Ending cryptococcal meningitis deaths by 2030: Strategic framework

Urgent boost and ‘reality check’ needed for HIV and TB funding, says new MSF report

Burden sharing or burden shifting?

We’re all still waiting, Gilead ...

Beware the Global Fund Procurement Cliff

Gilead Sciences fails on promise to expand access to lifesaving drug for people living with HIV

Then & Now in Access to Medicines: Changes & Challenges

Hundreds of thousands of people’s treatment at risk as countries ‘transition’ from Global Fund support

MSF Access calls on Gilead to urgently make its life-saving cryptococcal meningitis treatment more accessible and affordable

MSF calls on Mylan to urgently make its life-saving cryptococcal meningitis treatment more accessible and affordable